Mariner’s Standard BioTools LAB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$43.4K Buy
47,157
+27,529
+140% +$33.3K ﹤0.01% 3440
2025
Q4
$25.1K Sell
19,628
-42
-0.2% -$56 ﹤0.01% 3466
2025
Q3
$25.6K Sell
19,670
-8,521
-30% -$11.2K ﹤0.01% 3499
2025
Q2
$33.8K Sell
28,191
-45,954
-62% -$50.9K ﹤0.01% 3378
2025
Q1
$80.1K Buy
+74,145
New +$104K ﹤0.01% 3228
2024
Q4
Sell
-10,180
Closed -$19.6K 3460
2024
Q3
$19.6K Sell
10,180
-1,941
-16% -$3.8K ﹤0.01% 3252
2024
Q2
$21.5K Sell
12,121
-11,507
-49% -$28.1K ﹤0.01% 3107
2024
Q1
$64K Buy
+23,628
New +$57K ﹤0.01% 3001

Other funds holding LAB

Mariner's LAB Position: Q1 2026 in Review

Mariner increased its Standard BioTools (LAB) stake by 140% in Q1 2026, buying an estimated $33.3K and bringing the position to 47,157 shares worth $43.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3440.

Mariner first reported a position in LAB in Q1 2024 and has held it in 8 quarters since. The position peaked at $80.1K in Q1 2025. 155 funds tracked by Wall St. Rank hold LAB as of Q1 2026.

  • Mariner held 47,157 shares of Standard BioTools worth $43.4K as of Q1 2026.
  • Mariner bought 27,529 Standard BioTools shares in Q1 2026, an estimated $33.3K.
  • Standard BioTools made up ﹤0.01% of Mariner's portfolio in Q1 2026, its #3440 holding.
  • Mariner first reported a position in Standard BioTools in Q1 2024 and has held it in 8 quarters since.
  • Mariner's Standard BioTools position peaked at $80.1K in Q1 2025.
  • 155 funds tracked by Wall St. Rank held Standard BioTools as of Q1 2026.

Based on Mariner's 13F filing for Q1 2026, filed 13 May 2026.